


Amendments to the Claims:

Listing of Claims:

Claim 1. (Currently amended) A compound of formula



I

wherein

R<sub>1</sub> is (C<sub>1-4</sub>)alkyl;

R<sub>2</sub> is unsubstituted (C<sub>1-4</sub>)alkyl or (C<sub>1-4</sub>)alkyl substituted by unsubstituted or substituted

- (C<sub>6-18</sub>)aryl or

wherein the substituents are

- quinolinyl,
- benzo[1,3]dioxolyl,
- phenyl,
- phenyl one or morefold substituted by halogen, halo(C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, cyano, amino, dimethylamino, carboxy (C<sub>1-2</sub>)alkylcarbonylamino, amino(C<sub>1-2</sub>)alkylcarbonylamino, (C<sub>2-4</sub>)alkylenecarbonylamino, or heterocyclylcarbonyl(C<sub>1-2</sub>)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, and O; or
- (C<sub>6-18</sub>)aryl annelated with heterocyclyl having 5 or 6 ring members and 1 to 4 heteroatoms selected from N, O, and S; and

wherein the substituents are

- halogen
- unsubstituted amino or amino substituted by one or two (C<sub>1-4</sub>) alkyl,
- cyano
- (C<sub>1-4</sub>) alkoxy, or
- (C<sub>1-6</sub>) haloalkyl, and

R<sub>3</sub> is (C<sub>6-18</sub>)aryl one or morefold substituted by

- halogen,
- halo(C<sub>1-6</sub>)alkyl,
- halo(C<sub>1-6</sub>)alkoxy,
- cyano,
- phenyl, or

- heterocyclyl having 5 to 6 ring members and 1 to 4 heteroatoms selected from N, O, and S.

Claim 2. (Previously presented) A compound of claim 1 wherein

R<sub>1</sub> is methyl;

R<sub>2</sub> is methyl or


methyl substituted by

- quinoliny,
- benzo[1,3]dioxolyl,
- phenyl,
- phenyl one or morefold substituted by halogen, halo(C<sub>1-4</sub>)alkyl, (C<sub>1-4</sub>)alkoxy, cyano, amino, dimethylamino, carboxy(C<sub>1-2</sub>)alkylcarbonylamino, amino(C<sub>1-2</sub>)alkylcarbonylamino, (C<sub>2-4</sub>)alkylenecarbonylamino, or heterocyclylcarbonyl(C<sub>1-2</sub>)alkylcarbonylamino, wherein heterocyclyl has 6 ring members and 2 heteroatoms selected from N, and O;

- R<sub>3</sub> is phenyl one or morefold, substituted by

- halogen,
- halo(C<sub>1-2</sub>)alkyl,
- halo(C<sub>1-2</sub>)alkoxy,
- cyano,
- phenyl, or
- heterocyclyl, including aromatic, having 6 ring members and 2 nitrogen heteroatoms.

Claim 3. (Previously presented): A compound of claim 1 of formula



Claim 4. (Previously presented) A compound of claim 1 in the form of a pharmaceutically acceptable salt.

Claims 5-6 (Canceled)

Claim 7. (Previously presented): A pharmaceutical composition comprising a compound of formula I according to claim 1 in association with at least one pharmaceutical excipient.

Claim 8. (Previously presented): A pharmaceutical composition according to claim 7, further comprising another pharmaceutically active agent selected from compounds active in immunomodulating regimens or other anti-inflammatory agents.

Claim 9. (Currently amended): A method for treatment of inflammatory diseases, ~~allergic conditions, autoimmune diseases, or transplantation rejections~~ allergic contact dermatitis in a subject in need of such treatment, which method comprises administering to said subject an effective amount of a compound of formula I according to claim 1.

Claim 10. (Currently amended): A method for treatment of inflammatory diseases, ~~allergic conditions, autoimmune diseases, or transplantation rejection~~ allergic contact dermatitis in a subject in need of such treatment, wherein a compound of claim 1 is administered in combination with another pharmaceutically active agent selected from compounds active in immunomodulatory regimens or other anti-inflammatory agents, either simultaneously or in sequence.

Claim 11. (Previously presented): A compound selected from the group consisting of

- 2-[3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[5-Methyl-2-oxo-4-(quinoline-6-yl-acetyl(3-trifluoromethyl-phenyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(4-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(2-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Bromo-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-Biphenyl-3-yl-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3,5-Dichloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(4-Chloro-3-trifluoromethyl-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Chloro-4-fluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[5-Methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-3-(2-trifluoromethyl-phenyl)-[1,4]diazepam-1-yl]-3-naphthalen-1-yl-propionamide,

- 2-[3-(3,4-Difluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Cyano-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[5-Methyl-2-oxo-3-(3-pyrimidin-5-yl-phenyl)-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide, e.g. (R)-2-[5-Methyl-2-oxo-3-(3-pyrimidin-5-yl-phenyl)-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[5-Methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-fluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-4-fluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-cyano-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-phenylacetyl-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-[(3-trifluoromethyl-phenyl)-acetyl]-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-Biphenyl-4-yl-5-methyl-2-oxo-4-[2-(2,3,6-trichloro-phenyl)-acetyl]-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-[2-(4-Cyano-phenyl)-acetyl]-3-(3,4-difluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Chloro-phenyl)-4-[2-(4-cyano-phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-[2-(4-Amino-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-[2-(4-Amino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-[2-(4-Dimethylamino-phenyl)-acetyl]-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,

- 2-[4-[2-(3-Amino-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-7-methyl-3-oxo-2-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid,
- N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid,
- N-(3-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-succinamic acid,
- 2-[4-[2-[4-(2-Amino-acetyl-amino)-phenyl]-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-[2-[3-(2-Amino-acetyl-amino)-phenyl]-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-[2-[4-(3-Amino-propionyl-amino)-phenyl]-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-acrylamide,
- N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-morpholin-4-yl-4-oxo-butylamide,
- N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]-2-oxo-ethyl}-phenyl)-4-oxo-4-piperazin-1-yl-butylamide,
- 2-[3-(3-Chloro-phenyl)-4-[2-(2-methoxy-phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-(3-Chloro-phenyl)-4-[2-(4-methoxy-phenyl)-acetyl]-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[4-[2-(3-Chloro-4-methoxy-phenyl)-acetyl]-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide and
- 2-[4-Acetyl-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide.

Claim 12. (Previously presented): A compound selected from the group consisting of

- (R)-2-[3,5-cis-3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[3,5-cis-5-Methyl-2-oxo-4-(quinolin-6-yl-acetyl)-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[3,5-cis-3-(4-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[3,5-cis-3-(2-Fluoro-phenyl)-5-methyl-2-oxo-4-(quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,

- 2-[3,5-cis-3-(3-Bromo-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- 2-[3-Biphenyl-3-yl-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3,5-Dichloro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(4-Chloro-3-trifluoromethyl-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3-Chloro-4-fluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-5-Methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-3-(2-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3,4-Difluoro-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3-Cyano-phenyl)-5-methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[5-Methyl-2-oxo-3-(3-pyrimidin-5-yl-phenyl)-4-(2-quinolin-6-yl-acetyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-5-Methyl-2-oxo-4-(2-quinolin-6-yl-acetyl)-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3,5-cis-3-(3-fluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-chloro-4-fluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-3-(3-cyano-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-(2-Benzo[1,3]dioxol-5-yl-acetyl)-5-methyl-2-oxo-3-(3-trifluoromethoxy-phenyl)-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-5-methyl-2-oxo-4-phenylacetyl-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,
- (R)-2-[3,5-cis-3-(3-Fluoro-phenyl)-5-methyl-2-oxo-4-[(3-trifluoromethyl-phenyl)-acetyl]-[1,4]diazepan-1-yl]-3-naphthalen-1-yl-propionamide,

- 3,5-cis-2-{3-Biphenyl-4-yl-5-methyl-2-oxo-4-[2-(2,3,6-trichloro-phenyl)-acetyl]}-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-(4-Cyano-phenyl)-acetyl]}-3-(3,4-difluoro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(4-cyano-phenyl)-acetyl]}-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-(4-Amino-phenyl)-acetyl]}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-(4-Amino-phenyl)-acetyl]}-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-(4-Dimethylamino-phenyl)-acetyl]}-5-methyl-2-oxo-3-(3-trifluoromethyl-phenyl)-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-(3-Amino-phenyl)-acetyl]}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- N-(4-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]}-2-oxo-ethyl)-phenyl)-succinamic acid,
- N-(3-{2-[4-(1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]}-2-oxo-ethyl)-phenyl)-succinamic acid,
- (R)-2-[(3S,5R)-4-[2-{4-(2-Amino-acetyl-amino)-phenyl}-acetyl]}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-{3-(2-Amino-acetyl-amino)-phenyl}-acetyl]}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-{4-(3-Amino-propionyl-amino)-phenyl}-acetyl]}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- N-(4-{2-[4-((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]}-2-oxo-ethyl)-phenyl)-acrylamide,
- N-(4-{2-[(2S,7R)-4-((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]}-2-oxo-ethyl)-phenyl)-4-morpholin-4-yl-4-oxo-butylamide,
- N-(4-{2-[(2S,7R)-4-((R)-1-Carbamoyl-2-naphthalen-1-yl-ethyl)-2-(3-chloro-phenyl)-7-methyl-3-oxo-[1,4]diazepan-1-yl]}-2-oxo-ethyl)-phenyl)-4-oxo-4-piperazin-1-yl-butylamide,
- (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(2-methoxy-phenyl)-acetyl]}-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-3-(3-Chloro-phenyl)-4-[2-(4-methoxy-phenyl)-acetyl]}-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide,
- (R)-2-[(3S,5R)-4-[2-(3-Chloro-4-methoxy-phenyl)-acetyl]}-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepan-1-yl}-3-naphthalen-1-yl-propionamide, and

- (R)-2-[(3S,5R)-4-Acetyl-3-(3-chloro-phenyl)-5-methyl-2-oxo-[1,4]diazepam-1-yl]-3-naphthalen-1-yl propionamide.

Claims 13 - 17. (Canceled)

Claim 18. (Currently amended): A method pharmaceutical composition of claim 8 wherein the other pharmaceutical active agent is selected from cyclosporins, rapamycins ascomycins, corticosteroids, cyclophosphamide, azathioprene, methotrexate, FTY 720, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualine, immunosuppressive monoclonal antibodies, selectin antagonists or VLA-4 antagonists.

Claim 19. (Currently amended): A method pharmaceutical composition according to claim 18 wherein the other pharmaceutical active agent is cyclosporin A, cyclosporine G, FK506, ASM981, or monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45, CD58 or their ligands.

Claim 20. (Previously presented): A method according to claim 10 wherein the other pharmaceutical active agent is selected from cyclosporins, rapamycins ascomycins, corticosteroids, cyclophosphamide, azathioprene, methotrexate, FTY 720, leflunomide, mizoribine, mycophenolic acid, mycophenolate mofetil, 15-deoxyspergualine, immunosuppressive monoclonal antibodies, selectin antagonists or VLA-4 antagonists.

Claim 21. (Previously presented): A method according to claim 20 wherein the other pharmaceutical active agent is cyclosporin A, cyclosporine G, FK506, ASM981, or monoclonal antibodies to MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD40, CD45, CD58 or their ligands.

Claim 22. (Previously presented) The composition of claim 7 wherein the compound is the compound of claim 2.

Claim 23. (Previously presented): The composition of claim 7 wherein the compound is the compound of claim 3.

Claim 24. (Previously presented): The composition of claim 7 wherein the compound is the compound of claim 11.

Claim 25. (Previously presented): The composition of claim 7 wherein the compound is the compound of claim 12.

Claim 26. (Previously presented): The method of claim 9 wherein the compound is the compound of claim 2.



Claim 27. (Previously presented): The method of claim 9 wherein the compound is the compound of claim 3.

Claim 28. (Previously presented): The method of claim 9 wherein the compound is the compound of claim 11.

Claim 29. (Previously presented): The method of claim 9 wherein the compound is the compound of claim 12.